CDK1 Acts as a Prognostic Biomarker Associated with Immune Infiltration in Pan-Cancer, Especially in Gastrointestinal Tumors
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cyclin-dependent kinase 1 (CDK1) is overexpressed in most cancers and linked to poor prognosis. High CDK1 expression correlates with tumor mutational burden, immune cell infiltration, and poorer survival, suggesting its potential as a prognostic biomarker and immunotherapy target.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Cyclin-dependent kinase 1 (CDK1) is crucial for cell cycle regulation.
- Elevated CDK1 expression is frequently observed in various tumors and associated with adverse clinical outcomes.
- Understanding CDK1's role in pan-cancer is vital for developing targeted therapies.
Purpose Of The Study
- To evaluate the prognostic significance of CDK1 across multiple cancer types.
- To investigate the relationship between CDK1 expression and tumor immune microenvironment.
- To explore CDK1's association with tumor mutational burden and microsatellite instability.
Main Methods
- Bioinformatic analysis of CDK1 expression and survival data from pan-cancer databases.
- Assessment of immune cell infiltration using ESTIMATE and CIBERSORT algorithms.
- Correlation analysis of CDK1 with tumor mutational burden (TMB), microsatellite instability (MSI), and immune-related genes.
Main Results
- CDK1 is overexpressed in most tumors, particularly gastrointestinal cancers, and linked to poor survival in several types (e.g., KIRP, LIHC, LUAD, PAAD, PRAD, SARC).
- CDK1 expression correlates with TMB in 22 cancers and MSI in 8 cancers, notably in UCEC, STAD, SARC, READ, MESO, HNSC, and COAD.
- CDK1 levels are associated with infiltrating immune cells (macrophages, T cells, B cells) and show significant co-expression with 47 immune-related and immune checkpoint genes.
Conclusions
- CDK1 plays a significant role in cancer development and metastasis across various tumor types.
- CDK1 serves as a potential prognostic biomarker for patient outcomes.
- CDK1 represents a promising therapeutic target for cancer immunotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...